Scientists probe hidden resistance in prostate cancer radiation treatment
NCT ID NCT05435495
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at why some prostate cancers stop responding to a type of targeted radiation therapy called PSMA radioligand therapy. Researchers will use scans and tumor biopsies from 125 people starting this treatment to measure radiation doses and check gene activity linked to resistance. The goal is to learn more about how resistance develops, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering
RECRUITINGNew York, New York, 10065, United States
-
University of California, Los Angeles
RECRUITINGLos Angeles, California, 90095, United States
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?